Virological features associated with the development of broadly neutralizing antibodies to HIV-1

Trends in Microbiology

Volumn 23, Issue 4, 2015, Pages 204-211

  Moore, Penny L ^a,b,c   Williamson, Carolyn ^c,d   Morris, Lynn ^a,b,c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Broadly neutralizing antibodies; HIV 1; Immunotypes; Superinfection; Vaccine; Viral evolution

Indexed keywords

CD4 ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROTEIN BG505; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AMINO ACID SEQUENCE; B CELL CULTURE; BINDING AFFINITY; CD4 LYMPHOCYTE COUNT; CELL LINEAGE; CELL MATURATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; IMMUNOGENICITY; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; VIROGENESIS; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RELEASE; VIRUS STRAIN; BIOSYNTHESIS; GENETIC VARIABILITY; GENETICS; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; SOUTH AFRICA; VIROLOGY; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; EVOLUTION, MOLECULAR; GENETIC VARIATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; SOUTH AFRICA; VIRAL LOAD;

EID: 84925844719     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.12.007     Document Type: Review

References (83)

1. Gray E.S., et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 2007, 81:6187-6196.
2. Richman D.D., et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4144-4149.
3. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
4. Moore P.L., et al. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 2008, 82:1860-1869.
5. Moore P.L., et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009, 5:e1000598.
6. Rong R., et al. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J. Virol. 2007, 81:1350-1359.
7. Rong R., et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 2009, 5:e1000594.
8. Li Y., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 2009, 83:1045-1059.
9. Sather D.N., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:757-769.
10. Simek M.D., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009, 83:7337-7348.
11. Stamatatos L., et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 5:866-870.
12. Gray E.S., et al. HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 2011, 85:4828-4840.
13. Euler Z., et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 2010, 201:1045-1053.
14. Hraber P., et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014, 28:163-169.
15. Haynes B.F., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286.
16. Rerks-Ngarm S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
17. Derdeyn C.A., et al. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr. Opin. HIV AIDS 2014, 9:210-216.
18. Euler Z., et al. Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals. PLoS ONE 2013, 8:e54684.
19. Locci M., et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013, 39:758-769.
20. Cohen K., et al. Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J. Virol. 2014, 88:13310-13321.
21. Ackerman M., Alter G. Mapping the journey to an HIV vaccine. N. Engl. J. Med. 2013, 369:389-391.
22. West A.P., et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014, 156:633-648.
23. Klein F., et al. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341:1199-1204.
24. Mascola J.R., Haynes B.F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 2013, 254:225-244.
25. Haynes B.F., et al. Progress in HIV-1 vaccine development. J. Allergy Clin. Immunol. 2014, 134:3-10.
26. Pejchal R., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
27. Walker L.M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
28. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
29. Wu X., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
30. Blattner C., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014, 40:669-680.
31. Falkowska E., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014, 40:657-668.
32. Scharf L., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014, 7:785-795.
33. Huang J., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
34. Kong L., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
35. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554.
36. Scheid J.F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
37. Verkoczy L., et al. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 2011, 23:383-390.
38. Doria-Rose N.A., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014, 509:55-62.
39. Briney B.S., et al. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 2012, 7:e36750.
40. Piantadosi A., et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 2009, 83:10269-10274.
41. Rademeyer C., et al. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007, 368:172-181.
42. Moore P.L., et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 2012, 18:1688-1692.
43. Dugast A.S., et al. An inflammatory profile that predicts the development of neutralizing antibody breadth. AIDS Res. Hum. Retroviruses 2014, 30:A35-A36.
44. de Silva T.I., et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J. Virol. 2012, 86:930-946.
45. Kong R., et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J. Virol. 2012, 86:947-960.
46. Ozkaya Sahin G., et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J. Virol. 2012, 86:961-971.
47. Hraber P., et al. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J. Virol. 2014, 88:12623-12643.
48. Gnanakaran S., et al. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 2010, 6:e1000955.
49. van den Kerkhof T.L., et al. HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology 2013, 10:102.
50. Liao H.X., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476.
51. Hoot S., et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013, 9:e1003106.
52. Jardine J., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
53. McGuire A.T., et al. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J. Virol. 2014, 88:2645-2657.
54. Xiao X., et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2009, 390:404-409.
55. McGuire A.T., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 2013, 210:655-663.
56. Powell R.L., et al. Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J. Virol. 2010, 84:9415-9426.
57. Cortez V., et al. HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog. 2012, 8:e1002611.
58. Frost S.D., et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18514-18519.
59. Wei X., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.
60. Wu X., et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J. Virol. 2012, 86:5844-5856.
61. Moore P.L., et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J. Virol. 2013, 87:4882-4894.
62. Sather D.N., et al. Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. J. Virol. 2012, 86:12676-12685.
63. van Gils M.J., et al. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J. Virol. 2010, 84:3576-3585.
64. Wibmer C.K., et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013, 9:e1003738.
65. Euler Z., et al. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J. Virol. 2012, 86:2045-2055.
66. Gray E.S., et al. Antibody specificities associated with neutralization breadth in plasma from HIV-1 subtype C infected blood donors. J. Virol. 2009, 83:8925-8937.
67. Tomaras G.D., et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 2011, 85:11502-11519.
68. Langedijk J.P., Schuitemaker H. A sweet surprise for HIV broadly neutralizing antibodies. Nat. Med. 2012, 18:1616-1617.
69. Gao F., et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 2014, 158:481-491.
70. Bonsignori M., et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 2012, 86:4688-4692.
71. Mikell I., Stamatatos L. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. PLoS ONE 2012, 7:e49610.
72. Klein F., et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 2012, 209:1469-1479.
73. Sather D.N., et al. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J. Virol. 2014, 88:12968-12981.
74. Mahalanabis M., et al. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 2009, 83:662-672.
75. Murphy M.K., et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog. 2013, 9:e1003173.
76. Moore P.L., et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 2011, 85:3128-3141.
77. Goo L., et al. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 2014, 20:655-658.
78. Lyumkis D., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
79. Julien J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
80. Pissani F., et al. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine 2012, 30:5519-5526.
81. Malherbe D.C., et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 2011, 85:5262-5274.
82. Haynes B.F., et al. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30:423-433.
83. Malherbe D.C., et al. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J. Virol. 2014, 88:12949-12967.